Philips beats earnings forecast as it mobilises for respiratory device recall
Reuters
Published Jul 26, 2021 01:47AM ET
Updated Jul 26, 2021 04:01AM ET
By Sarah Morland
(Reuters) -Dutch health technology company Philips on Monday beat analysts' expectations with a jump in second-quarter core earnings to 532 million euros ($626 million), boosted by its personal health and diagnosis businesses. Analysts had expected adjusted earnings before interest, taxes and amortisation (EBITA) to rise to 519 million euros, up from 390 million euros a year earlier.
The group also announced a 1.5 billion euro share buyback set to start in the third quarter and take up to three years.
Comparable sales increased 9%, beating an average expectation of a 7.3% rise, though its sales were dragged by its sleep and respiratory care business.
The company booked an additional provision of 250 million euros as it works to repair and replace up to 4 million breathing devices and ventilators it recalled in June, bringing the total provision to 500 million euros.
Philips recalled the devices because of a foam part that might degrade and become toxic, potentially causing cancer.
The U.S. Food and Drug Administration (FDA) last week classified the recall of Philips' breathing devices and ventilators as the most serious type of recall, noting that over 1,200 complaints and 100 injuries had been reported.
In a call with reporters, Chief Executive Frans van Houten said the company was producing replacement and repair kits in anticipation of a green light from regulators, though once approved the deployment project could take up to 12 months due to the high number of devices in the field.
He added that the company was gathering evidence on the risks posed by the devices before the class action lawsuits that have been filed come to court.
Philips confirmed its 2021 sales growth forecast but narrowed down its profit margin expectations to the low end of its previous range.
($1 = 0.8492 euros)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.